Br J Ophthalmol 2000;84:1091-1096
( October )
Matrix metalloproteinases and their natural inhibitors in
fibrovascular membranes of proliferative diabetic retinopathy
Joel Salzmanna, G Astrid Limba, Peng T Khawa, Zdenek J Gregora, Lynne Websterb, Anthony H Chignellb, David G Charterisa
a Institute
of Ophthalmology and Moorfields Eye Hospital, London, UK, b St Thomas's Hospital, London
Correspondence to: Dr G A Limb, Department of Pathology, Institute of Ophthalmology,
11-43 Bath Street, London EC1V 9EL, UK
g.limb{at}ucl.ac.uk
Accepted for publication 23 May 2000
AIM To examine
epiretinal membranes of proliferative diabetic retinopathy (PDR) for
the presence of selective matrix metalloproteinases (MMPs) and their
natural inhibitors (TIMPs), in order to determine whether
neovascularisation and fibrosis, characteristic of this complication of
diabetes mellitus, are associated with specific anomalies of MMP or
TIMP expression.
METHODSThe presence
of selected MMPs and TIMPs was investigated in 24 fibrovascular
epiretinal membranes of PDR, and the findings compared with that
observed in 21 avascular epiretinal membranes of proliferative
vitreoretinopathy (PVR) and five normal retinas. Specimens were
examined for deposition of interstitial collagenase (MMP-1),
stromelysin-1 (MMP-3), gelatinase A (MMP-2), gelatinase B (MMP-9), and
three tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2, and
TIMP-3).
RESULTSThe results
showed that unlike normal retina, which constitutively expresses MMP-1
and TIMP-2, a large proportion of PDR membranes (> 62%) stained for
MMP-1, MMP-2, MMP-3, MMP-9, TIMP-1, TIMP-2, and TIMP-3. There were no
differences in the expression of these molecules when compared with PVR
membranes. A characteristic staining for MMP-9 was observed within the
perivascular matrix of PDR membranes, and there was a significant
increase in TIMP-2 expression by PDR membranes (p= 0.036) when compared
with PVR membranes.
CONCLUSIONSThe
findings that MMPs involved in degradation of fibrovascular tissue
matrix, as well as TIMP-1 and TIMP-2, are found in a large proportion
of PDR membranes, and that their expression does not differ from that
of PVR membranes, suggest the existence of common pathways of
extracellular matrix degradation in pathological processes leading to
retinal neovascularisation and fibrosis.
© 2000 by British Journal of Ophthalmology
This article has been cited by other articles:
|
|
|
|
 
D. Navaratna, G. Menicucci, J. Maestas, R. Srinivasan, P. McGuire, and A. Das
A peptide inhibitor of the urokinase/urokinase receptor system inhibits alteration of the blood-retinal barrier in diabetes
FASEB J,
September 1, 2008;
22(9):
3310 - 3317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. P. Kadoglou, S. S. Daskalopoulou, D. Perrea, and C. D. Liapis
Matrix Metalloproteinases and Diabetic Vascular Complications
Angiology,
March 1, 2005;
56(2):
173 - 189.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S L Ho, G F Dogar, J Wang, J Crean, Q D Wu, N Oliver, S Weitz, A Murray, P E Cleary, and C O'Brien
Elevated aqueous humour tissue inhibitor of matrix metalloproteinase-1 and connective tissue growth factor in pseudoexfoliation syndrome
Br. J. Ophthalmol.,
February 1, 2005;
89(2):
169 - 173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ohno-Matsui, T. Uetama, T. Yoshida, M. Hayano, T. Itoh, I. Morita, and M. Mochizuki
Reduced Retinal Angiogenesis in MMP-2-Deficient Mice
Invest. Ophthalmol. Vis. Sci.,
December 1, 2003;
44(12):
5370 - 5375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Noda, S. Ishida, M. Inoue, K.-i. Obata, Y. Oguchi, Y. Okada, and E. Ikeda
Production and Activation of Matrix Metalloproteinase-2 in Proliferative Diabetic Retinopathy
Invest. Ophthalmol. Vis. Sci.,
May 1, 2003;
44(5):
2163 - 2170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Priglinger, C. A. May, A. S. Neubauer, C. S. Alge, C.-L. Schonfeld, A. Kampik, and U. Welge-Lussen
Tissue Transglutaminase as a Modifying Enzyme of the Extracellular Matrix in PVR Membranes
Invest. Ophthalmol. Vis. Sci.,
January 1, 2003;
44(1):
355 - 364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Portik-Dobos, M. P. Anstadt, J. Hutchinson, M. Bannan, and A. Ergul
Evidence for a Matrix Metalloproteinase Induction/Activation System in Arterial Vasculature and Decreased Synthesis and Activity in Diabetes
Diabetes,
October 1, 2002;
51(10):
3063 - 3068.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Lambert, C. Munaut, M. Jost, A. Noel, Z. Werb, J.-M. Foidart, and J.-M. Rakic
Matrix Metalloproteinase-9 Contributes to Choroidal Neovascularization
Am. J. Pathol.,
October 1, 2002;
161(4):
1247 - 1253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hangai, N. Kitaya, J. Xu, C. K. Chan, J. J. Kim, Z. Werb, S. J. Ryan, and P. C. Brooks
Matrix Metalloproteinase-9-Dependent Exposure of a Cryptic Migratory Control Site in Collagen is Required before Retinal Angiogenesis
Am. J. Pathol.,
October 1, 2002;
161(4):
1429 - 1437.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Limb, J. T. Daniels, R. Pleass, D. G. Charteris, P. J. Luthert, and P. T. Khaw
Differential Expression of Matrix Metalloproteinases 2 and 9 by Glial Muller Cells : Response to Soluble and Extracellular Matrix-Bound Tumor Necrosis Factor-{alpha}
Am. J. Pathol.,
May 1, 2002;
160(5):
1847 - 1855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
